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Antibodies play major roles in immunity to malaria;
however, a limited understanding of mechanisms
mediating protection is a major barrier to vaccine
development. We have demonstrated that acquired
human anti-malarial antibodies promote comple-
ment deposition on the merozoite to mediate inhibi-
tion of erythrocyte invasion through C1q fixation
and activation of the classical complement pathway.
Antibody-mediated complement-dependent (Ab-C0)
inhibition was the predominant invasion-inhibitory
activity of human antibodies; most antibodies were
non-inhibitory without complement. Inhibitory activ-
ity was mediated predominately via C1q fixation,
and merozoite surface proteins 1 and 2 were identi-
fied as major targets. Complement fixation by anti-
bodies was very strongly associated with protection
from both clinical malaria and high-density parasite-
mia in a prospective longitudinal study of children.
Ab-C0 inhibitory activity could be induced by human
immunization with a candidate merozoite surface-
protein vaccine. Our findings demonstrate that
human anti-malarial antibodies have evolved to func-
tion by fixing complement for potent invasion-inhibi-
tory activity and protective immunity.
INTRODUCTION
Humoral responses to Plasmodium falciparum are an important
component of acquired immunity against malaria, as demon-
strated in pivotal studies in which immunoglobulin G (IgG) from
immune adults was transferred to malaria-infected children
and resulted in parasite clearance and recovery (Cohen et al.,580 Immunity 42, 580–590, March 17, 2015 ª2015 The Authors1961). Antibodies are thought to protect by inhibiting blood-
stage replication and preventing high-density parasitemia. How-
ever, specificmechanisms of protection are not well understood.
The merozoite stage, which infects red blood cells (RBCs), is an
important target, and antibodies to somemerozoite antigens can
inhibitP. falciparum replication in vitro (Hodder et al., 2001;Miura
et al., 2009; Reiling et al., 2012; Wilson et al., 2011). However,
antibodies targeting numerous merozoite antigens, including
vaccine candidates such as MSP2 and MSP3, lack activity in
these standard assays (McCarthy et al., 2011; Oeuvray et al.,
1994), despite some evidence of efficacy in clinical and pre-
clinical trials (Genton et al., 2002; Sirima et al., 2011). Indeed,
growth-inhibitory activity of human antibodies is not consistently
predictive of clinical immunity (Crompton et al., 2010; Dent et al.,
2008; Marsh et al., 1989; McCallum et al., 2008), and antibodies
from immune adults often fail to inhibit parasite replication
in standard assays (Dent et al., 2008; McCallum et al., 2008;
Shi et al., 1999). A lack of established immune correlates of
protection severely hampers the evaluation and prioritization of
vaccines (Beeson et al., 2014).
Overall reactivity of antibodies to merozoite antigens as
measured by ELISA correlates with protection in some, but not
all, human studies (Fowkes et al., 2010). Human antibodies to
merozoite antigens are predominantly cytophilic subclasses
IgG1 and IgG3; these have been associated with protection
from malaria (Polley et al., 2006; Richards et al., 2010; Roussil-
hon et al., 2007; Stanisic et al., 2009; Taylor et al., 1998). This rai-
ses the question of whether complement might be an important
effector of antibody function. Although complement activation
has been reported in malaria infection and innate activation
has been implicated in pathogenesis (reviewed in Biryukov and
Stoute, 2014), the role of complement in antibody-mediated pro-
tection has not been defined.
Here, we developed approaches and assays to determine the
ability of acquired human antibodies to fix complement and
inhibit merozoite invasion of RBCs and to identify major mero-
zoite targets of these antibodies. We evaluated antibody activity
in naturally exposed individuals from diverse geographic regions
and vaccinated humans, and we obtained epidemiologic
evidence supporting a role for antibody-mediated complement
fixation in protective immunity to malaria in children. Our findings
represent a major advance in understanding immunity to malaria
and provide a much-needed strategy for the development and
evaluation of vaccines.
RESULTS
Human IgG from Malaria-Exposed Donors Has
Complement-Dependent Inhibitory Activity
To assess the role of complement in antibody inhibition of inva-
sion, we performed merozoite-invasion assays in the presence
or absence of active complement (Boyle et al., 2010b; Figures
S1A and S1B). Merozoites were isolated from schizonts via
membrane filtration and incubated with uninfected RBCs
together with increasing concentrations of purified IgG (1/200
to 1/10 dilution) from malaria-exposed pooled donors (from
Kenya and Papua New Guinea [PNG]) in the presence of either
normal serum (NS; complement active) or heat-inactivated
serum (HIS; complement inactive). IgG from Kenyan donors
was non-inhibitory in HIS but effectively inhibited invasion
when incubated with NS (Figure 1A). IgG from PNG donors
had some activity in HIS, but inhibition was much greater in NS
(Figure 1A). IgG from malaria-naive donors (Australian residents)
was not inhibitory in NS or HIS, and the fact that NS did not
inhibit in the absence of IgG indicates that complement alone
is non-inhibitory (Figures S1C and S1D). The greater inhibition
of merozoite invasion by malaria-exposed IgG in NS than in
HIS suggests that IgG interacts with complement to inhibit
invasion. This identifies an invasion-inhibitory mechanism that
we refer to as antibody-mediated complement-dependent
(Ab-C0) inhibition. We will refer to inhibitory activity of antibodies
in the absence of complement (HIS) as direct antibody inhibition.
Complement fixation on merozoites incubated with malaria-
exposed IgG (PNG residents) or malaria-naive IgG (Australian
residents) was investigated via immunoblot. C1q and C3b
were detected at higher levels on merozoites incubated with
NS and PNG IgG than on merozoites incubated with Australian
IgG, reflecting activation of the classical complement cascade
by anti-merozoite antibodies (Figure 1B; Figures S1E and
S1F). Some C3b deposition was detected on merozoites
incubated with Australian IgG and NS, suggesting activation
of the antibody-independent alternate pathway. C3b deposition
was confirmed by immuno-electron microscopy; merozoite
surface-bound C3b was detected after incubation with PNG
IgG and NS, but not with HIS (Figure 1C; Figure S1G). The for-
mation of the membrane attack complex (MAC; components
C5–C9) was detected by immuno-fluorescence (IF) microscopy.
MAC formation was detected on merozoites incubated with
PNG IgG and NS. Lower MAC formation was seen with Austra-
lian IgG and NS (Figure 1D). Using an ELISA-based assay, we
quantified MAC deposition and demonstrated that it was sig-
nificantly higher (p < 0.01) with PNG IgG than with Australian
(Melbourne) IgG (Figure 1E). These data show that human
anti-malarial antibodies enhance complement deposition on
merozoites via C1q fixation and thus result in increased C3b
deposition and MAC formation.C1q Fixation Mediates Ab-C0 Inhibition
To test the importance of the activation of the classical comple-
ment cascade in relation to that of the alternative complement
cascade, we compared the invasion-inhibitory activity of anti-
malarial antibodies between NS and HIS heated at 50C for
20 min; this treatment inhibits the alternative complement
cascade by inactivating Factor B but leaves the classical com-
plement cascade intact. The 50C treatment of serum had no
significant effect on the invasion-enhancing activity; invasion
inhibition by PNG IgG was greater in the presence of NS and
50C-treated serum than in the presence of standard HIS (Fig-
ure S2A). This indicates that amplification of the alternative
pathway does not account for Ab-C0 inhibition. To address the
relative importance of different complement components, we
tested invasion inhibition in C1q- and C5-depleted serum and re-
constituted serum. There was significant enhancement of inva-
sion inhibition by PNG IgG in assays with C1q-reconstituted
serum in comparison to assays with C1q-depleted serum, which
was comparable to the greater inhibition in NS than in HIS (Fig-
ure 2A). In contrast, there was significantly less of a difference
in the extent of PNG IgG inhibition in C5-reconstituted serum
than in C5-depleted serum. This suggests that activation of the
classical complement cascade, specifically fixation of C1–C4,
might be sufficient to mediate the majority of Ab-C0 and that
deposition of C5–C9 is of less importance. To investigate this
further, we incubated merozoites with PNG or Australian IgG in
increasing concentrations of purified human C1q in the absence
of other complement factors. C1q substantially enhanced the
inhibitory activity of PNG IgG (Figure 2B), indicating that C1q fix-
ation alone was sufficient tomediate substantial Ab-C0 inhibition.
No inhibition was seen in the presence of control IgG or C1q.
To investigate whether MAC deposition and lysis could also
contribute to inhibiting invasion, we assessed the ability of IgG
and complement to lyse merozoites. Merozoite invasion occurs
rapidly, such that 80% of invasion occurs within 10 min of mixing
with RBCs (Boyle et al., 2010b); therefore, we assessed the lysis
of merozoites within this time period. Merozoites were incubated
with PNG or Australian IgG and 20% NS or HIS and counted by
flow cytometry (Figure 2C; Figure S2B). PNG IgG mediated a
significantly greater reduction in merozoites in NS than in HIS,
whereas there was little lysis of merozoites with Melbourne IgG.
Over an extended time period (30–60 min), lysis of merozoites
was observed in NS alone (Figure S2C), consistent with the low
rate of MAC formation in the absence of malaria-specific IgG
(Figure 1E). Rapid merozoite lysis was dependent on activation
of the classical complement cascade and was not an artifact of
agglutination, as confirmed by the lack of lysis in C1q-depleted
serum (Figure S2D). Using PNG IgG and 20% NS, analysis of
the timing of merozoite lysis revealed that lysis occurred rapidly,
such that the majority occurred within 2–3 min of incubation and
reached a maximum by 4 min (Figure 2D).
Ab-C0 Inhibition Is the Predominant Mechanism
Targeting Merozoite Invasion
The importance of Ab-C0 inhibition in naturally acquired immunity
was assessed with purified IgG from Kenyan (n = 33) and PNG
(n = 10) individuals. Overall, there was much greater Ab-C0
inhibition than direct inhibitory activity (Figure 3A). Compared
to direct inhibition, Ab-C0 inhibitory activity was seen in aImmunity 42, 580–590, March 17, 2015 ª2015 The Authors 581
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Figure 1. Invasion Inhibition by IgG and Complement and Complement Deposition on the Merozoite Surface
(A) Invasion-inhibitory activity of purified IgG from Kenya and PNG was tested in invasion assays performed with 50% normal serum (NS; complement active) or
heat-inactivated serum (HIS; complement inactivated). Data represent the mean ± range from two independent assays performed in duplicate.
(B) C1q and C3 deposition on merozoites incubated with purified PNG IgG, purified malaria-naive IgG (Australian donors), or PBS together with 25% NS for 1, 5,
15, and 30 min. MSP1-19, a merozoite surface protein, was used as a loading control.
(C) C3b deposition on merozoites incubated with purified PNG IgG and 25% NS or HIS via immuno-electron microscopy. Gold labeling is indicated with arrows.
Scale bars represent 0.1 mm.
(D) Formation of the membrane attack complex (MAC; complement components C5–C9) on merozoites incubated with purified PNG or Australian (Melbourne)
IgG and 25% NS or HIS via IF microscopy.
(E) MAC deposition as quantified by ELISA onmerozoites incubated with NS and PNG or Australian IgG. Immunoblots andmicroscopy images are representative
of two independent experiments.
See also Figure S1.much greater proportion of individuals (proportion positive
[defined as >15% inhibition]: 57.2% ± 8.7% for Ab-C0 and
21.2% ± 7.2% for direct inhibition; p < 0.01). These striking
results reveal that the majority of human antibodies require
complement factors to effectively inhibit merozoite invasion.
The extent of inhibitory activity varied widely. In Kenyan indi-
viduals, four activity profiles were observed: (1) no inhibitory
activity in NS or HIS (11/33 [33%]); (2) invasion enhancement
in HIS, but not NS (7/33 [21%]); (3) Ab-C0 inhibition only,
demonstrated by invasion inhibition in NS, but not HIS (10/33582 Immunity 42, 580–590, March 17, 2015 ª2015 The Authors[30%]); and (4) a combination of Ab-C0 inhibition and direct
inhibitory activity, demonstrated by inhibition in HIS and
increased inhibition in NS (5/33 [15%]) (Figure 3B; Figure S3A).
Among PNG individuals, 50% had Ab-C0 inhibitory activity
only, and the remaining samples had substantial direct inhibitory
activity (Figure 3C). Overall, 37% of samples had only com-
plement-dependent inhibitory antibodies. In those with both
complement-dependent and directly active antibodies, com-
plement-dependent inhibition ranged from 12% to 81% of the
total inhibitory response.
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Figure 2. C1q Fixation by IgG Inhibits Invasion, and Complement
Fixation Leads to Merozoite Lysis
(A) Invasion-inhibitory activity of purified PNG IgG (1/10 dilution) was tested in
the presence of 25% NS and HIS, C1q-depleted serum with and without
reconstitution with purified C1q, and C5-depeleted serum with and without
reconstitution with C5. The difference in invasion-inhibitory activity between
depleted and reconstituted serum was calculated. Data represent the
mean ± SEM from four to five independent assays performed in duplicate.
(B) Invasion-inhibitory activity of purified PNG IgG in the presence of increasing
concentrations (2.2–35 mm/ml) of purified C1q. Data show invasion as a
percentage of that of media alone and represent the mean ± range from two
independent assays performed in duplicate.
(C) Lysis of merozoites: merozoite concentration after 10-min incubation
with 1/20 dilution of purified PNG or purified malaria-naive Australian IgG
and 20% NS or HIS. Data show merozoite concentration as a percentage
of that of purified Australian IgG with HIS and represent the mean ± SEM from
three independent assays performed in duplicate.
(D) Lysis rate of merozoites incubated with purified PNG IgG and 20%
NS. Data show lysis as a percentage of the maximum and represent the
mean ± SEM from four independent assays.
See also Figure S2.Ab-C0 Inhibition Strongly Correlates with Cytophilic
Antibodies to Merozoites
In Kenyan individuals, we assessed the relationship among
Ab-C0 inhibition, direct inhibition, IgG subclass reactivity to
merozoites, and antibody activity in standard complement-free
growth-inhibition assays (GIAs). The prevalence of antibodies
tomerozoites was high, andmerozoite-specific IgGwas strongly
and significantly correlated with Ab-C0 inhibition, but not with
direct inhibitory activity and less strongly with activity in GIAs
(Table 1). Of note, the strongest correlation was between
Ab-C0 inhibition and IgG3 (Figure 3D). This relationship was
stronger than that seen for IgG1 and is consistent with the known
property of IgG3 as the most potent activator of complement.
Ab-C0 inhibition was also strongly correlated with age (Spear-
man’s r = 0.63, p = 0.0003), matching the acquisition of immu-
nity. In contrast, direct inhibitory activity only weakly correlated
with age (Spearman’s r = 0.17, p = 0.38). With a median invasion
in NS of 32.3% (95% CI = 54.7–82.2), Ab-C0 activity was alsogreater than activity in GIAs, whose median growth was 89.3%
(95% CI = 81–91, p = 0.007). Further, the proportion of individ-
uals with positive Ab-C0 inhibition increased with age, and
100% of adults had Ab-C0 inhibitory activity; only 44% had direct
activity (Figure 3E). These results strongly suggest that Ab-C0 is
the predominant mechanism of antibodies targeting merozoite
invasion and is acquired in naturally exposed individuals as im-
munity to malaria develops.
C1q Fixation by Antibodies Correlates with Ab-C0
Inhibition
Having shown that Ab-C0 inhibition functions via fixation of C1q
and the activation of the classical complement cascade, we
evaluated the relationship between C1q deposition and Ab-C0
inhibition. We measured antibody-mediated C1q deposition on
merozoites by immunoblot using IgG from nine Kenyan individ-
uals with high, medium, or low Ab-C0 inhibition (n = 3 for each
group). C1q deposition was notably higher with IgG from individ-
uals who had high Ab-C0 inhibitory activity than with IgG from
those with medium or low activity (Figure 3F). Next, to quantify
C1q fixation on merozoites, we developed a high-throughput
plate-based assay that uses small sample volumes to allow
testing of large numbers of serum samples and that can be
used with small-volume pediatric samples (Figure S3B). Anti-
body-mediated C1q deposition on merozoites was strongly
correlated with Ab-C0 activity (Figure 3G). Samples that pro-
moted high C1q fixation also had high C3b fixation (Figure S3C).
This supports the important role of C1q fixation and activation of
the classical cascade in Ab-C0 inhibition and establishes an
efficient complement-deposition assay that is suitable for appli-
cation to clinical studies.
Antibodies that Fix Complement Are Associated
with Protection from Malaria
To obtain epidemiologic evidence of the importance of anti-
body-mediated complement fixation in acquired immunity to
malaria, we tested antibodies for C1q fixation from a longitudi-
nal cohort of 206 5- to 14-year-old children who were resident
in a malaria-endemic region of PNG (Michon et al., 2007); all
children were treated for malaria parasitemia at enrollment
and then monitored by active surveillance for parasitemia
and clinical malaria over 6 months of follow-up. The preva-
lence of antibody-mediated C1q fixation on the merozoite
surface was very high (Table S1), reflective of substantial
exposure to malaria in this population. Antibody-mediated
C1q deposition was associated with age, such that older
children had significantly higher C1q deposition than younger
children (Figure 4A; Figure S4). C1q deposition was also
higher in children who were parasitemic at the time of sample
collection than in aparasitemic children (Figure 4B). The in-
crease in antibody-dependent C1q deposition with age and
parasitemia is consistent with the expected acquisition of
immunity.
To assess the role of antibody-mediated C1q fixation in pro-
tection from symptomatic malaria and high-density parasitemia,
we grouped children into low, medium, and high categories of
C1q-fixation activity; we then compared the relative risk of
malaria between response groups. High C1q deposition was
very strongly associated with protection from clinical malaria
(Table 2). The association between antibodies and protection
from malaria appeared to have a dose-response relationshipImmunity 42, 580–590, March 17, 2015 ª2015 The Authors 583
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Figure 3. Ab-C0 Is the Predominant Mechanism of Naturally Acquired Antibodies and Correlates with C1q-Deposition Activity
(A) Invasion-inhibitory activity of purified IgG from Kenyan and PNG individuals in 50% NS or HIS (median ± interquartile range).
(B) Invasion-inhibitory activity of purified IgG fromKenyan individuals in the presence of NS andHIS; shown are no inhibitory activity (blue), invasion-enhancement
activity (in HIS and not NS, yellow), Ab-C0 inhibition (orange), and Ab-C0 and direct inhibitory activity (red). Data represent the mean ± range from two independent
assays performed in duplicate.
(C) Invasion-inhibitory activity of purified IgG from PNG individuals.
(D) IgG3 reactivity to the merozoite surface as measured by ELISA correlated with functional activity in Ab-C0 assays. Data show invasion as a percentage of that
of the control.
(E) Significant activity in invasion-inhibition assays with 50% NS or HIS was defined as <85% invasion (>15% inhibition); data show the proportion of individuals
with activity, and individuals are stratified by age. p values are shown for comparisons of the proportion of samples that were positive in assays using NS between
the 1–6 and 7–13 age groups and between the 1–6 and >13 age groups. The p value is also shown for the comparison of the proportion of positive samples in
the >13 age group between assays using NS and assays using HIS.
(F) C1q deposition on merozoites was assessed by immunoblot for nine purified Kenyan IgG samples that had high, medium, or low Ab-C0 inhibitory activity. The
image is representative of two independent assays. Abbreviations are as follows: Melb, pool of Melbourne IgG included as a negative control; PNG, pool of PNG
IgG included as a positive control.
(G) Measured by ELISA, C1q deposition on merozoites in purified Kenyan IgG samples correlated with Ab-C0 inhibitory activity (n = 33).
See also Figure S3.(Figure 4C); high responders had fewer symptomatic episodes
than did medium or low responders. Numerous variables were
explored as possible confounding factors; only subject age
and location of residence were significantly associated with
risk of malaria (Michon et al., 2007). The strong protective asso-
ciation for antibody-mediated C1q deposition remained after
adjustment for age and location of residence (p < 0.0001), and
protective associations were observed for children who were584 Immunity 42, 580–590, March 17, 2015 ª2015 The Authorsparasitemic or aparasitemic at enrollment (Figure S4B). High
C1q deposition was also strongly associated with protection
from episodes of high-density parasitemia (>5,000 parasites/
ml), which remained significant after adjustment for confounders
(Table 2; Figure 4D). These data are consistent with a role for
antibody-mediated complement fixation and Ab-C0 inhibition in
limiting blood-stage replication of P. falciparum and preventing
disease.
Table 1. Correlation between Invasion-Inhibition Assays and
GIAs and Antibodies to the Merozoite Surface
Antibody
Prevalenceb
Functional Activitya
IIA-Ab-C0 IIA-Direct GIA
rc p rc p rc p
Total IgG 82% 0.57 <0.001 0.18 0.31 0.41 0.02
IgG1 85% 0.56 <0.001 0.13 0.49 0.32 0.07
IgG2 55% 0.46 0.01 0.37 0.04 0.52 0.001
IgG3 52% 0.73 <0.0001 0.16 0.37 0.48 0.005
IgG4 3% 0.49 0.07 0.07 0.70 0.3 0.09
aFunctional activity of individuals was measured in invasion-inhibition as-
says with NS (IIA-Ab-C0) and HIS (IIA-direct) and in a standard GIA that
measures growth-inhibitory activity over two invasion cycles in comple-
ment-free conditions.
bThirty-three Kenyan serum samples were tested for total IgG, IgG1,
IgG2, IgG3, and IgG4 on the merozoite surface by ELISA. Positive re-
sponses were defined as greater than the mean optical-density values
of Australian (Melbourne) controls plus 3 SDs.
cSpearman correlation coefficients.MSP1 and MSP2 Are Targets of Ab-C0 Inhibitory
Antibodies
To identify merozoite antigens that are targets of Ab-C0 inhibition,
we tested rabbit antibodies to several major merozoite surface
antigens for inhibition of invasion in the presence of NS or HIS.
Antibodies to MSP1-19, MSP1 block 2, and MSP2 substantially
inhibited invasion in the presence of NS, but not HIS (Figure 5A).
Activity was specific, and no inhibition was seen with antibodies
from non-immunized rabbits (data not shown). Antibodies to the
MAD20-like MSP1 block 2 alleles used in the parasite line tested
(MAD20 and Wellcome alleles) inhibited invasion, whereas anti-
bodies to heterologous K1-like (3D7 or Palo Alto) alleles did
not, reflecting the strain specificity of the antibodies. It is notable
that some antibodies to MSP2 and MSP1 block 2 enhanced
invasion in HIS, as was seen with some antibodies from naturally
exposed subjects (Figure 3), whereas they were inhibitory in
the presence of NS. With rabbit antibodies to MSP3, MSP4,
and AMA1, we observed minimal differences in invasion-inhibi-
tory activity between NS and HIS.
MSP2 and MSP3 are vaccine candidates that have pro-
gressed to clinical trials, but development has been hampered
by the lack of immunologic correlates of protection, given that
these antibodies are relatively non-inhibitory in standard GIAs
(McCarthy et al., 2011; Oeuvray et al., 1994). The function of
human antibodies to MSP2 and MSP3 was defined with affin-
ity-purified antigen-specific human antibodies in invasion-inhibi-
tion assays (Figure 5B). In agreement with results from rabbit
antibodies, purified human anti-MSP2 antibodies significantly
inhibited invasion in NS, but not in HIS. In contrast, MSP3 anti-
bodies showed a limited amount of direct inhibitory activity
and no enhancement by complement.
To further confirm the role of complement fixation in mediating
invasion inhibition and the significance of MSP2 as a target, we
tested a human MSP2-specific monoclonal antibody (mAb)
with and without a specific change (L234A or L235A [LALA]) in
the amino acid sequence of the Fc region (Stubbs et al., 2011);
this change ablates binding to C1q and complement activationbut leaves binding to the antigen unaffected (Hessell et al.,
2007). Significantly greater invasion inhibition in NS than in HIS
was only seen with wild-type MSP2 mAb and not with the modi-
fied mAb. Further, invasion inhibition was greater in NS with the
wild-type than in NS with the altered mAb. These results further
confirm the importance of C1q fixation in Ab-C0 inhibition and
MSP2 as a target.
Ab-C0 Inhibitory Antibodies Can Be Induced by Human
Immunization
We examined whether Ab-C0 inhibitory activity could be induced
by immunization of malaria-naive individuals with recombinant
merozoite surface proteins. We studied samples from the recent
phase 1 clinical trial of the MSP2-C1 vaccine (McCarthy et al.,
2011). IgG from ten individuals with high C1q-fixation activity
(as defined by ELISA) were tested for invasion-inhibitory activity
in NS and HIS (Figures 5D and 5E). IgG from these individuals
lacked inhibitory activity in standard GIAs despite high antibody
reactivity by ELISA (McCarthy et al., 2011). Notably, eight of
ten individual IgG samples showed substantial inhibition in NS,
but not in HIS, indicating the induction of Ab-C0 inhibition by
vaccination. No inhibition was seen in IgG from pre-vaccinated
individuals or placebo-vaccinated samples (Figure S5). These
data indicates that MSP2 antibodies induced by vaccination
are able to inhibit invasion via Ab-C0 inhibition and identify a po-
tential mechanism mediating the protective efficacy of MSP2-
based vaccines (Genton et al., 2002).
DISCUSSION
Although the importance of antibody in immunity to malaria has
been established (Cohen et al., 1961), mechanisms mediating
protection are poorly understood. Here, we provide evidence
that complement plays a key role in antibody-mediated immunity
to malaria in humans. Antibodies from malaria-exposed individ-
uals enhanced complement fixation on merozoites and had sub-
stantially greater invasion-inhibitory activity in the presence of
complement. Ab-C0 inhibition was the predominant mechanism
inhibiting invasion, and many antibodies were only inhibitory
in the presence of complement factors. Our findings indicate
that the mechanism underlying this activity is predominately
mediated by C1q fixation. Antibody-complement interactions
also led to merozoite lysis. Targets of Ab-C0 include the
most abundant merozoite surface antigens, MSP1 and MSP2.
Furthermore, we provide epidemiologic evidence of the role of
antibody-complement interactions in human immunity by
demonstrating that C1q fixation was very strongly associated
with protection from clinical malaria and high-density parasite-
mia in a prospective longitudinal study of children. Finally, we
demonstrated that Ab-C0 inhibition can be induced by human
immunization, providing an important proof of concept for trans-
lation into malaria vaccine development.
Comparisons of Ab-C0 inhibitory activity in serum depleted
and reconstituted with C1q or C5 highlight the importance of
C1q in mediating inhibition of invasion. Further, C1q alone
was able to significantly enhance the inhibitory activity of anti-
malarial antibodies in the absence of other complement factors.
This was further demonstrated by comparison of wild-type and
altered human MSP2 mAbs; Ab-C0 inhibition was only seenImmunity 42, 580–590, March 17, 2015 ª2015 The Authors 585
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Figure 4. C1q Fixation by Antibodies Is
Associated with Protection from Malaria
Antibody-mediated C1q deposition on the mero-
zoite surface was measured in plasma from a
cohort of 206 children in PNG.
(A) C1q deposition was higher in older children
(>9 years; n = 115).
(B) C1q deposition was higher in children with
concurrent P. falciparum infection (n = 139) than in
uninfected children, as determined by PCR.
(C) High C1q fixation by antibodies was strongly
associated with reduced risk of clinical malaria
episodes. Children were divided into three groups
on the basis of high, medium, and low C1q-fixing
antibodies.
(D) High antibody-mediated C1q fixation was
associated with reduced risk of high-density
parasitemia.
See also Figure S4.with the wild-type and not the altered mAb. C1q-mediated anti-
body neutralization has been previously reported with influenza
(Feng et al., 2002) and West Nile virus (Mehlhop et al., 2009).
Enhanced inhibition by C1qmight be due to increased steric hin-
drance by the large (460-kDa) C1q-IgG complex blocking bind-
ing of parasite proteins to cellular receptors or through the stabi-
lization of IgG of low avidity. In complement-free systems, some
antibodies to MSP1 (Blackman et al., 1994; Dluzewski et al.,
2008) and MSP2 (Boyle et al., 2014) can be internalized into
the RBC while bound to the merozoite surface without
inhibiting invasion. However, in the presence of complement,
antibodies to MSP2 and MSP1 effectively inhibit invasion. The
C1q-IgG complex might be too large to be internalized during
invasion, thereby mediating the inhibitory activity of antibodies
that are otherwise not directly inhibitory.
Although C1q-mediated enhancement appears central to in-
vasion-inhibitory activity, complement deposition and lysis of
merozoites are likely to have other implications in vivo, including
enhancement of phagocytosis and induction of pro-inflamma-
tory cytokines that might further mediate control of parasitemia.
Complement activation, particularly as part of the innate immune
response, has been implicated in pathogenesis as a result of
induction of inflammatory responses (reviewed in Biryukov andTable 2. Association between Antibody-Mediated C1q Deposition o
High-Density Parasitemia
uHR (95% CI)
Clinical malaria LvM 0.56 (0.34–0.94)
LvH 0.12 (0.05–0.28)
High-density parasitemia LvM 0.80 (0.50–1.30)
LvH 0.26 (0.13–0.49)
The cohort was stratified into three equal groups according to low, medium, o
and HRs adjusted for age and location of residence (aHRs) were calculated t
the risk of symptomatic malaria or high-density parasitemia (>5,000 parasite
episode only.
586 Immunity 42, 580–590, March 17, 2015 ª2015 The AuthorsStoute, 2014; Silver et al., 2010). In the absence of anti-malarial
antibodies, complement did not inhibit merozoite invasion,
despite some deposition of C3b and MAC on the parasite
surface and the eventual lysis of merozoites in the absence of
malaria-exposed IgG with extended incubations. This is most
likely due to the reduced rate and extent of complement deposi-
tion in the absence of specific antibody and might also indicate
that merozoites could be able to inhibit complement activation,
as described for other pathogens (Lambris et al., 2008).
Testing antibodies from various individuals demonstrated that
Ab-C0 inhibition was the predominant mechanism for inhibition
of invasion; the extent of inhibition and the prevalence of Ab-C0
inhibition were greater than direct antibody inhibition, and
Ab-C0 inhibition increased with age, reflective of the known
acquisition of immunity. Strong epidemiologic evidence of the
importance of complement fixation in antibody-mediated
immunity to malaria was established in a longitudinal cohort of
children acquiring immunity. High-C1q-fixing antibodies were
very strongly associated with protection from clinical malaria.
Furthermore, complement fixation was strongly associated
with protection from high-density parasitemia, consistent with
the proposed role of Ab-C0 inhibition in limiting parasite replica-
tion and thereby preventing disease. These findings providen the Merozoite Surface and Protection from Clinical Malaria and
p aHR (95% CI) p
0.028 0.64 (0.38–1.09) 0.1
<0.0001 0.15 (0.06–0.35) <0.0001
0.37 0.94 (0.58–1.53) 0.804
<0.0001 0.35 (0.18–0.70) 0.003
r high C1q reactivity (see also Table S1). Unadjusted hazard ratios (uHRs)
o compare low-versus-medium (LvM) or low-versus-high (LvH) groups for
s/ml) over the time period of 6 months. Calculations were based on the first
AC D E
B Figure 5. MSP1 and MSP2 Are Targets of
Ab-C0 Inhibition, and Ab-C0 Inhibition Is
Induced by Human Vaccination
(A) Invasion-inhibitory activity of rabbit antibodies
specific to merozoite surface antigens in the
presence of 50% NS and HIS. Data represent the
mean ± range from two independent assays
performed in duplicate.
(B) Invasion-inhibitory activity of naturally ac-
quired human affinity-purified MSP2 and MSP3
antibodies at 50 mg/ml in the presence of 50% NS
or HIS. Data represent the mean ± SEM from four
independent assays performed in duplicate.
(C) Invasion inhibition with human mAbs (IgG1)
to MSP2 in the presence of 50% NS or HIS (mAb
concentration 50 mg/ml). Recombinant MSP2
mAb was expressed with the wild-type sequence
or with a LALA Fc mutation, which is known to
ablate C1q fixation. Two independent assays
were performed in duplicate.
(D) Invasion-inhibitory activity of purified IgG from
malaria-naive adults immunized with recombinant
MSP2 antigen was tested in the presence of 50%
NS or HIS at a 1/2 dilution of the original concentration. Data represent the mean ± range from two independent assays performed in duplicate.
(E) Overall, inhibitory activity by IgG from individuals receiving the MSP2 vaccine was greater when it was tested in the presence of 50% NS than when it was
tested in the presence of HIS.
See also Figure S5.insight into the potential role of complement fixation in protective
humoral immunity in humans and contrast with the limited
and inconsistent associations reported for antibody activity
measured in standard GIAs. The GIA is performed in comple-
ment-free conditions and is currently the only widely used func-
tional assay of antibodies to merozoites (Crompton et al., 2010;
Dent et al., 2008; John et al., 2004; Marsh et al., 1989; McCallum
et al., 2008; Wilson et al., 2011). We propose that the weak and
inconsistent correlation between standard GIAs and malaria im-
munity reflects the central importance of complement factors in
mediating antibody activity. Further, Ab-C0 inhibition strongly
correlated with reactivity of cytophilic antibodies to merozoites,
particularly IgG3. This fits with the properties of IgG3 as the
most potent activator of complement and is consistent with find-
ings that ELISA titers of IgG3 to merozoite antigens are associ-
ated with protection in human cohort studies (Courtin et al.,
2009; Ndungu et al., 2002; Nebie et al., 2008; Richards et al.,
2010; Roussilhon et al., 2007; Stanisic et al., 2009). Merozoite
proteins MSP1 and MSP2 were identified as important targets
of Ab-C0 inhibition. Antibodies to MSP1 block 2 and MSP2
show limited inhibition in standard GIAs (Boyle et al., 2014;
Cowan et al., 2011; Flueck et al., 2009; Galamo et al., 2009; Mc-
Carthy et al., 2011). The block 2 region of MSP1 is polymorphic
and under balancing selection, suggesting immune pressure.
Consistent with this, the Ab-C0 inhibitory activity of MSP1 block
2 antibodies was strain specific, supporting the view that poly-
morphisms have evolved to mediate immune evasion.
Our studies have established a proof of principle that Ab-C0
inhibitory antibodies can be induced by human vaccination
with recombinant merozoite surface antigens with the use
of samples from a phase 1 trial of the MSP2-C1 vaccine.
A vaccine based on MSP2 was previously found to have sig-
nificant protective efficacy against P. falciparum parasitemia
in a naturally exposed population in PNG (Genton et al., 2002).However, the mechanism of protective function of MSP2 anti-
bodies has been unclear (McCarthy et al., 2011). Here, we have
shown that antibodies to MSP2 interact with complement to
inhibit invasion. The identification of Ab-C0 activity as a central
protectivemechanism of antibodies targetingmerozoite antigens
might suggest a role for this assay in evaluating candidate vac-
cines. Unlike the phase 2 vaccine trial of MSP2, a phase 2
trial of aMSP1 42-kDaC-terminal construct (MSP1-42) had no ef-
ficacy in a naturally exposed population in Kenya (Ogutu et al.,
2009). Vaccine failure might be explained by antigenic diversity,
given that only a single allele of the polymorphicMSP1-42antigen
was included, or by the nature, epitope specificity, or concentra-
tionof antibodies induced; the vaccinemight have failed to induce
strong complement-fixing antibodies to effectively inhibit inva-
sion, which could be investigated in future studies.
In conclusion, we have identified Ab-C0 inhibition as a promi-
nent mechanism targeting the merozoite in naturally acquired
immunity, and we found that complement-dependent inhibition
can be mediated by antibodies induced by human immunization
with a recombinant merozoite surface-protein vaccine. Our find-
ings demonstrate that human anti-malarial antibodies have
evolved to function in the presence of complement by recruiting
complement for functional activity and protective immunity.
These insights mark a major change in our understanding of
mechanisms of functional immunity and provide tools for evalu-
ating naturally acquired and vaccine-induced immunity. Our
findings might have translational implications, indicating that
focusing on targets and strategies that induce strong comple-
ment-fixing antibodies might be an important step in the devel-
opment of highly efficacious vaccines.EXPERIMENTAL PROCEDURES
Further details can be found in the Supplemental Experimental Procedures.Immunity 42, 580–590, March 17, 2015 ª2015 The Authors 587
Parasite Culture, Synchronization, and Invasion-Inhibition Assays
The P. falciparum D10-GFP expression line was cultured as previously
described and synchronized with heparin (Boyle et al., 2010a; Wilson et al.,
2010). Invasion-inhibition assays were performed as described in Boyle
et al. (2010a); merozoites were incubated with uninfected RBCs, normal or
heat-inactivated serum (NS or HIS, respectively), and test IgG for 30 min (Fig-
ure S1A). Cells were washed and cultured for 40 hr and then analyzed via flow
cytometry. NS and HIS was from malaria-naive donors. For heat inactivation,
sera were heated at 56C for 30 min. For assays testing the importance of the
alternative pathway, sera were heat inactivated at 50C for 20 min. For assays
testing the importance of C1q and C5 for Ab-C0 activity, human serum
depleted of C1q or C5 and purified human C1q and C5 (Calbiochem, Merck)
were used at 25% concentration. GIAs were performed as described in
Persson et al. (2006).
Human Subjects and Samples
Ethical approval for the use of human serum and plasma samples in these
studies was obtained from the Alfred Human Research and Ethics Committee
for the Burnet Institute, from the Kenya Medical Research Institute, from the
Medical Research Advisory Committee of Papua New Guinea, and from the
Human Research and Ethics Committee of theQueensland Institute ofMedical
Research. Written informed consent was obtained from all participants or,
in the case of children, from their parents or guardians. Serum pools from ma-
laria-exposed donors were made from serum samples from Kenya (Ngerenya,
Kilifi District) and PNG (Madang District). Unexposed serum pools were from
Australian donors residing in Melbourne (Australia Red Cross Blood Bank).
IgG from serum pools was purified with Melon Gel according to the manufac-
turer’s (Thermo Scientific) instructions. Purified IgG was concentrated in 10-
kDa MWCO (molecular weight cutoff) spin-purification tubes (Amicon) and
buffer exchangedwith PBS. For the longitudinal study of PNG children, plasma
samples were obtained at enrollment from a prospective treatment-reinfection
cohort of 206 children aged 5–14 years (median = 9.3) in Madang, PNG (Mi-
chon et al., 2007). Children were actively reviewed every 2weeks for symptom-
atic illness and parasitemia, and by passive case detection, over a period of
6 months. A clinical episode of P. falciparum malaria was defined as fever
and P. falciparum parasitemia >5,000 parasites/ml. Serum samples were
used from a phase 1 MSP2-C1 vaccine trial in which participants were immu-
nized with both 3D7 and FC27 MSP2 isoforms formulated with Montanide ISA
720 (McCarthy et al., 2011) (sponsored by PATH Malaria Vaccine Initiative;
Trial Registration, AWZCTR 12607000552482).
Rabbit and Human Antibodies to Specific Merozoite Antigens
Rabbit sera were raised against recombinant proteins corresponding to
MSP1-19, MSP1 block 2, MSP4, MSP2, the MSP3 C-terminal region, and
AMA1 (3D7 and 7G8 alleles) as described in Boyle et al. (2014) and Drew
et al. (2012). Human antibodies to MSP2 (FC27) and MSP3 (K1) were purified
fromPNGandKenyan serumdonors via column chromatography according to
established methods (Reiling et al., 2012). A human mAb to MSP2 was
previously isolated from a malaria-exposed donor and expressed as recombi-
nant IgG1 with the wild-type sequence or with a Fc-LALA mutation (Stubbs
et al., 2011).
Complement Deposition Assays via Immunoblot, ELISA,
and Microscopy
Merozoites were incubated with 25% NS and test IgG or serum samples for 1,
5, 10, 15, or 30 min at 37C. Merozoites were washed and solubilized for
immunoblot analysis. C1q and C3 were detected with anti-C1q (Goat poly-
clonal, Calbiochem, Merck) and anti-C3 (HRP-conjugated goat polyclonal,
MP Biomedicals), respectively.
For ELISA, plates were coated with purified merozoites at 5 3 106 merozo-
ites/well. Plates were blocked and then incubated with sera samples (1/250),
and then recombinant C1q (10 mg/ml) and C1q were detected with goat anti-
C1q antibodies and anti-goat-HRP. C1q and C3 deposition was also detected
with C5-depleted serum as a complement source. For ELISA analysis of MAC
deposition, isolated merozoites were incubated with 25% NS serum and IgG
from PNG or Australian (Melbourne) serum pools for 10 min at 37C and
then washed and coated into Nunc 96-well plates. Plates were blocked, and588 Immunity 42, 580–590, March 17, 2015 ª2015 The Authorsthe presence of MAC was detected with anti-C5–C9 antibodies (rabbit) fol-
lowed by anti-rabbit-HRP.
For immuno-electron microscopy, merozoites were incubated with NS or
HIS with PNG IgG for 10 min. Merozoites were washed and fixed in 1% glutar-
aldehyde and then processed and imaged as described in Boyle et al. (2010a).
For IF microscopy, merozoites were incubated with 25% NS serum and IgG
from PNG or Melbourne donors for 10 min (37C). Merozoites were washed
and dried on slides, fixed with methanol, and blocked, and then MAC was
detected with anti-C5–C9 antibodies (rabbit) and anti-rabbit-Alexa 488 anti-
bodies. Images were obtained as described in Reiling et al. (2012).
Assays of Merozoite Lysis
Merozoites were incubated with 5% PNG or Melbourne IgG and 20%NS, HIS,
or C1q-depleted serum for 10 min (37C); for assays to assess the rate of
merozoite lysis, an aliquot of sample was taken every minute for analysis
by flow cytometry. Samples were diluted 1/100 in 200 ml cold PBS and 1%
newborn calf serum, and the density of merozoites was counted with Count-
Bright counting beads via flow cytometry.
ELISA to Intact Merozoites
ELISAs were performed according to standard methods (Stanisic et al., 2009).
Purified merozoites were coated in PBS and placed on microtiter plates.
Merozoites were blocked and subsequently incubated with Kenya serum sam-
ples diluted at 1/250 and then sheep anti-human IgG HRP diluted at 1/2,500.
Data Analysis
Differences in invasion-inhibitory IgG activity between NS and HIS and be-
tween C1q-depleted and -reconstituted serum were calculated with paired
t tests in Stata/SE 11.2. Associations between antibody reactivity to intact
merozoites by ELISA and functional activity in assays of Ab-C0 inhibition, direct
inhibition, and growth inhibition were assessed with Spearman’s correlations
calculated in Prism.
Analysis of the cohort study was performed with Stata/SE 12.0. Differences
in C1q deposition between groups were assessed by chi-square tests (for cat-
egorical variables) or Wilcoxon rank-sum tests (for continuous variables). For
assessment of associations between C1q deposition and protection, subjects
were stratified into tertiles according to low (including those classified as
‘‘negative’’), medium, or high deposition of C1q, as determined by optical-den-
sity values for each sample. Groups were compared for risk of clinical malaria
(fever and >5,000 parasites/ml) or high-density parasitemia (>5,000 parasites/
ml) with the Cox proportional-hazards model (Reiling et al., 2010; Richards
et al., 2010). Survival analysis included first episodes only. Age and location
of residence were previously identified as potential confounders from a range
of factors (Stanisic et al., 2009).
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at http://
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